Tarcocimab and Tabirafusp for Wet Age-Related Macular Degeneration

Tarcocimab and Tabirafusp for Wet Age-Related Macular Degeneration
80%69%58%May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 27 • YES 66.6%May 28 • YES 71.4%
Kodiak Sciences Inc ($KOD)
No stock close$37.89$35.92$33.94May 18May 19May 20May 21May 22May 23May 24May 25May 26May 27May 28May 18 • KOD $35.02May 19 • KOD $34.42May 20 • KOD $36.22May 21 • KOD $37.41May 22 • KOD $36.23May 26 • KOD $36.00May 27 • KOD $35.09May 28 • KOD $36.12

Will this trial show a positive result on best corrected visual acuity (BCVA), Mean change in BCVA from Day 1 to Year 1, Week 48?

Paper Trading
Create account to trade
ClinicalNewsTrialPositionsReasoningOracle

Matched news2 items

All news
KOD

Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham

Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of sham-treated

Trial Results • Phase 3Matched tarcocimab, macular, tedromer
KOD

Final APEX Phase 1b Clinical Results for Kodiak's KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026

PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis (Angiogenesis,

Presentation / Abstract • Phase 1Matched tarcocimab, macular, degeneration